Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 3Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Solid Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Malignant Ascites 1Lung Neoplasms 1Glioma 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Malignant Ascites × Nivolumab × Clear all
NCT05745233 2023-08-24

Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

China Medical University Hospital

Phase NA Enrolling by invitation
30 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡